| |
| REVIEWS |
Cardiac Gene Therapy: Are We There Yet?
The reviewers summarize the gene delivery carriers, modes of delivery, recent preclinical/clinical studies and potential therapeutic targets. They briefly discuss the existing limitations of gene therapy, technical challenges surrounding gene carriers and delivery systems, and some approaches to overcome these limitations for bringing cardiovascular disease gene therapy one step closer to reality. [Gene Ther] Abstract
Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research fields.
|
| | | SCIENCE NEWS |
Phase II Cervical Cancer Study with Advaxis’ Axalimogene Filolisbac Selected for Poster Discussion Session
The poster, “ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the Phase II GOG/NRG0265 study,” was selected as one of 12 abstracts to be featured. [Press release from Advaxis, Inc. discussing research to be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release
Heat Biologics and OncoSec Present Data
Heat Biologics, Inc. announced that preclinical data from its collaboration with OncoSec Medical Incorporated focused on evaluating the combination of immunotherapy platforms were presented. [Press release from Heat Biologics, Inc. discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release
Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy
Vycellix, Inc. announced that its CEO, Evren Alici, M.D., Ph.D., will present. The company expects to initially advance its technology for the treatment of hematological malignancies and sarcomas. [Press release from Vycellix, Inc. discussing research presented at the Innate Killer Summit 2016, San Diego] Press Release
Asterias Biotherapeutics Announces Oral Presentation
Asterias Biotherapeutics, Inc. announced that clinical data from its AST-VAC1 (antigen-presenting autologous dendritic cells) immunotherapy clinical program will be presented during an oral session. [Press release from Vycellix, Inc. discussing research presented at the American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting, Washington, D.C.] Press Release
|
| | | BUSINESS |
Homology Medicines Inc. Launches as a Newly-Formed Genetic Medicines Company Founded Upon a Unique City of Hope Gene Editing and Gene Transfer Platform Technology
City of Hope announced that it has licensed its pioneering AAV-based gene editing technology exclusively to Homology Medicines Inc. A City of Hope lab led by Saswati Chatterjee, Ph.D., developed the single platform technology that enables both gene editing and gene therapy with a built-in in vivo delivery system. [City of Hope (Business Wire)] Press Release
Regenerating Blood Vessels Gets $2.7 Million Grant
Biomedical engineers at The University of Texas at Austin have received a three-year, $2.7 million grant from the U.S. Department of Defense to advance a promising treatment that could help millions of people with diabetes affected by peripheral ischemia, a condition that restricts blood flow to muscles in the lower limbs. [The University of Texas at Austin] Press Release
Queen’s Researchers in €2.25m International Project to Tackle Diabetes-Related Blindness
The new €2.25m US-Ireland R&D partnership is bringing together a unique team of scientists and clinicians to develop a gene therapy approach with the aim of potentially reversing diabetes-linked blood vessel damage to the retina – the light-sensitive tissue at the back of the eye. Ultimately, the team hopes to prevent disease progression and restore visual function. [Queen’s University Belfast] Press Release
TRACT Therapeutics, Inc. Received FDA Approval for a Phase II Trial Using a Patient’s Immune Cells to Prevent Organ Rejection
TRACT Therapeutics, Inc. announced that it received Food and Drug Administration (FDA) approval to initiate a Phase II clinical trial to investigate the efficacy and safety of its novel therapy for kidney transplant recipients. [TRACT Therapeutics, Inc. (Business Wire)] Press Release
Regenerating Brain Tissue Brings Hope for a New Treatment against Alzheimer’s and Parkinson’s
Mexican researchers developed a nanogel that enables the growth of new neurons. Working with animal models, Mexican researchers were able to cross the electroencephalic barrier, introduce a nanogel and achieve the growth of neurons within the gel, which shows that it is possible to promote regeneration of brain tissue. [Investigación y Desarrollo (AlphaGalileo)] Press Release
First Gene Therapy Successful Against Human Aging
The 44 year-old CEO of BioViva USA Inc. Elizabeth Parrish received two of her own company’s experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion responsible for diverse age-related diseases and infirmities. [BioViva USA Inc.] Press Release
Dr. Patrick Soon-Shiong Honored at the Vatican with the 2016 Pontifical Key Visionary Award
Dr. Patrick Soon-Shiong, who grew up in Apartheid South Africa and has dedicated his life to pioneering novel cellular therapies for diabetes and cancer, including the development of the revolutionary cancer drug Abraxane, was honored at the Vatican with the 2016 Pontifical Key Visionary Award. [Business Wire] Press Release
University of Wisconsin and Harvard Scientists Receive Awards from ASNTR
ASNTR awarded The 2016 Bernard Sanberg Memorial Award for Brain Repair to Marina E. Emborg, MD, PhD, an associate professor of medical physics at the University of Wisconsin-Madison. ASNTR also presented The Molly and Bernard Sanberg Memorial Award to Eng H. Lo, PhD, professor of neurology and radiology at Harvard University and Massachusetts General Hospital. [University of South Florida (EurkeAlet!)] Press Release
|
|
